Leading translational research to accelerate & advance personalized and targeted therapies against cancer. @iCERCA centreThe Vall d’Hebron Institute of Oncology (VHIO) is a reference center for personalized medicine in oncology created in 2006. Thanks to its pioneering model of multidisciplinary and translational research and its participation in consortia and projects with

Core values

- **Translational Cancer Research**: VHIO is a leading center in translational cancer research, focusing on the prevention, early diagnosis, and treatment of cancer. This directly improves patient outcomes and contributes to the advancement of cancer care[5].
- **Personalized Medicine**: VHIO is a reference center for personalized medicine in oncology, which enhances treatment efficacy and patient quality of life[5].
- **International Collaborations**: VHIO participates in numerous international consortia, such as the Comprehensive Cancer Infrastructures for Europe (CCI4EU) and the EuroPDX Consortium, which facilitate knowledge sharing, accelerate access to novel therapeutics, and improve cancer care across Europe[3].
- **Environmental and Health Initiatives**: The Green VHIO initiative aims to reduce environmental impact and advocate for environmental protection in cancer prevention, which addresses broader societal and health issues[1].
- **Scientific and Clinical Innovations**: VHIO's research includes pioneering projects on biomarkers, cell-based therapies, and novel imaging strategies, all of which contribute to advancing medical science and improving patient care[2][3].